Regulatory Intelligence · Advisory · Applied Policy

Reading complex systems early. Building what works — and the bridges between.

I help organizations see proposed rules coming, understand what they really do, and respond with comment letters and advocacy built to hold up — substantively and legally.

Founder, Iota Intel LLC Frisco, Texas United States & the Gulf

§ 01  Profile

Two decades inside the rules.

I spent more than fifteen years in senior regulatory affairs at one of the nation's largest health enterprises, through the director level — leading a regulatory team at Optum that kept policies compliant across the healthcare and prescription-drug delivery chain, for multiple payer types and lines of business.

Before that, I was a firefighter. It's a strange line on a résumé for a regulatory advisor, but the instinct is the same: read the situation fast, act on what matters, and stay calm where the stakes are real. Today I run Iota Intel LLC, an independent regulatory intelligence and advisory practice.

My work reaches beyond the U.S. I have engagements and active interest across the Gulf — where I've recently been building new relationships and partnerships — and ties to entrepreneurship and education programs from Central Asia to the former Soviet Union. I think a good deal about how regulation, and cooperation more broadly, can build bridges between countries rather than friction. This page is the person behind the practice — what I do, what I've written, and what I'm working toward.

MIM, Thunderbird School of Global Management  ·  MBA, W. P. Carey · Arizona State  ·  B.A. International Relations, University of Minnesota

§ 02  Practice

What I do for clients.

  • a. Regulatory analysis & docket monitoring
    Watching open dockets in your space, flagging what matters early, and translating dense proposed rules into plain implications and decisions.
  • b. Comment letters & rulemaking advocacy
    Submission-quality letters that combine statutory analysis, peer-reviewed evidence, international benchmarking, and durable legal framing — written to be read by agency career staff and to stand up after the fact.
  • c. Advisory & market-entry strategy
    Counsel for organizations navigating regulation, with healthcare and benefits as my core and selective international engagements across the GCC.

The firm itself — services, engagement models, and the full body of work — lives at iotaintel.com.

§ 03  Selected Filings

Proof of work, on the public record.

CMS-0062-P

Drug prior authorization & interoperability standards

A comment grounded in global FHIR-adoption evidence and a voluntary industry pledge — pairing U.S. rulemaking with international benchmarking.

EPA-HQ-OW-2022-0946

EPA Draft Sixth Contaminant Candidate List (CCL 6)

A fully sourced comment on the agency's draft CCL 6 — a 34-footnote evidentiary framework, framed for durability in the post–Loper Bright environment.

EPA-HQ-OPP-2024-0431

Partial revocation of chlorpyrifos tolerances

A close legal read of a proposed pesticide-tolerance rule — tested against the FFDCA standard, the agency's duty to respond to significant comments, and the narrowed deference landscape after Loper Bright.

§ 04  Lines of Inquiry

What I'm working toward.

  • Framework

    Mutually Assured Prosperity

    A deliberate inversion of mutually-assured-destruction logic: the idea that nations, like parties to a rule, often have more room for mutual creation than the loudest players assume — and that good policy can build cooperation rather than friction.

  • Circular economy

    Bioconversion & waste-to-value

    Work I've long championed alongside a thirty-year collaborator: using black soldier fly larvae to upcycle organic waste into feed and oils, with potential further applications in chitin, melanin, and peptides. These are areas of active exploration, not finished product claims.

  • Public health

    Clean water & health spending

    Two threads that connect my regulatory work to bigger questions: the durability of drinking-water protections, and what America's health spending reveals about where regulation helps and where it doesn't — a bridge, too, to healthcare collaboration prospects in the Gulf.

§ 05  Contact

Start a conversation.

Whether you're a client navigating a consequential rule, a collaborator on one of the ideas above, or simply curious — I'd welcome the conversation.